Abstract:BACKGROUND: About 9% of children have asthma, corresponding to almost 6.8 million children in the USA and 1.1 million in the UK. Asthma exacerbations are the leading cause of pediatric emergency room visits and impose a large burden on the individual, family, and society. There is mounting evidence that therapeutic failure of inhaled beta-agonists is associated with polymorphisms of the beta(2)-adrenergic receptor gene (ADRB2); specifically, mutations leading to amino acid changes at positions 16 and 27, which alter down-regulation of the beta(2)-adrenergic receptor (beta(2)AR), induce resistance to the smooth-muscle relaxing effect of beta(2)-adrenergic agonists.METHODS: We conducted a meta-analysis to examine the association between ADRB2 polymorphisms and the response to inhaled beta(2)-adrenergic agonists in children with asthma. We included all published studies until November 2008, in which asthmatic children underwent testing for acute bronchodilator response, defined as > or = 15% improvement in forced expiratory volume in 1 second (FEV(1)) and single nucleotide polymorphism (SNP) genotyping for positions 16 and/or 27 of the beta(2)AR. Individual and summary odds ratios were calculated using a random effects model.RESULTS: We identified three case-control or family-based studies involving 960 asthmatic children (692 children with negative beta(2)-bronchodilator response, defined as < 15% improvement in FEV(1) and 268 children with positive bronchodilator response). We found a significant association between favorable therapeutic response to inhaled beta(2)-adrenergic agonists in asthmatic children and the Arg/Arg phenotype at position 16 of the beta(2)AR [OR = 1.77; 95% CI (1.01; 3.1); p = 0.029], compared with the Arg/Gly or Gly/Gly phenotypes. The beneficial effect of Arg at position 16 of the beta(2)AR was most pronounced in African-American asthmatic children [OR = 3.54; 95% CI (1.37, 9.13)]. There was no association between clinical response to beta(2)-agonists and polymorphism at amino acid position 27 of the beta(2)AR (OR = 1.04; 95% CI [0.76,1.42]).CONCLUSIONS: Failure of bronchodilator response to inhaled beta-agonists in asthmatic children is associated with the Gly allele (Arg/Gly and Gly/Gly genotypes) at position 16 of the beta(2)-adrenergic receptor. Genetic typing for beta(2)AR polymorphism may help identify children with drug-resistant asthma.

Pharmacogenetics of beta2 adrenergic receptor agonists in asthma management

Asthma pharmacogenetics and the development of genetic profiles for personalized medicine

Pharmacogenetic and pharmacogenomic considerations of asthma treatment

Pharmacogenomics of Β2-Adrenergic Receptor Agonists in Asthma Therapy

Pharmacogenetics of Asthma Therapy

Pharmacogenetic Factors Affecting Asthma Treatment Response. Potential Implications for Drug Therapy

Trends in pharmacogenomics of drugs used in the treatment of asthma

Pharmacogenomics of Acute Asthma: The β2-Adrenergic Receptor Gene as a Model for Future Therapy

Pharmacogenomics of pediatric asthma

Advance in Search for Pharmacogenomics of Asthma

Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in asthma

How to Control Asthma with Personalized Management: Where Do We Stand Now?

Polymorphism of the ADRB2 Gene and Response to Inhaled Beta- agonists in Children with Asthma: A Meta-analysis

Genomic Predictors of Asthma Phenotypes and Treatment Response

A Genome-Wide Association Study of Bronchodilator Response in Asthmatics

Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers

The impact of genomic variants on patient response to inhaled bronchodilators: a comprehensive update

Understanding how long-acting β2 -adrenoceptor agonists enhance the clinical efficacy of inhaled corticosteroids in asthma - an update

Pharmacogenomics of Leukotriene Modifiers: A Systematic Review and Meta-Analysis

Effect of Β2-Adrenergic Receptor Polymorphisms on Childhood Asthma and Therapeutic Efficacy of Long-Acting Β2-Agonist

Effect of pharmacogenomics on beta receptor blockers